Key facts
- Germany's Federal Drug Commissioner Dr. Hendrik Streeck is personally open to adult-use cannabis pilot projects.
- Streeck acknowledged that the trend of cannabis consumption cannot be simply reversed.
- The pilot projects were part of 'Pillar 2' of Germany's CanG act, focusing on commercial adult-use frameworks.
- The German Cannabis Business Association welcomed Streeck's intervention, noting successful pilot projects in Switzerland and the Netherlands.
- Concerns exist about the blurring lines between medical and recreational cannabis use, with a proposed removal of flower from statutory health insurance reimbursement.
Germany's Federal Drug Commissioner, Dr. Hendrik Streeck, has indicated a personal openness to exploring limited, scientifically monitored adult-use cannabis pilot projects, a stance that could signal a shift in the country's drug policy landscape. This comes as the Christian Democratic Union (CDU), which previously pledged to roll back the CanG act, faces internal discussions and external pressure. Streeck acknowledged the reality of widespread cannabis consumption, stating that the trend cannot be ignored or simply reversed. He expressed willingness to consider pilot projects under strict conditions, including no normalization, commercial expansion, advertising, or distribution to young adults, with limited quantities and close scientific monitoring. The German Cannabis Business Association welcomed Streeck's intervention, citing successful examples in Switzerland and the Netherlands. However, concerns persist regarding the blurring lines between medical and recreational cannabis use. The German Federal Institute for Drugs and Medical Devices reported a 16.8% drop in cannabis flower imports in Q1 2026 compared to the previous quarter, though imports were still significantly higher than the previous year. A Finance Commission for Health recommended removing flower from statutory health insurance reimbursement, a move opposed by pharmacy and industry associations who warn it could push patients towards uncontrolled supply.